Cancers that affect women exclusively—breast, ovarian, cervical, and endometrial—are often treated in oncology as four separate organ sites, each with its own research silos, screening guidelines, and treatment pathways. A new editorial argues that this fragmented view misses the point. Writing in the journal Cancer Causes & Control, Editor-in-Chief Immaculata De Vivo of Harvard Medical School contends that these diseases are better understood as a single continuum of women’s lives, spanning menarche and contraception, pregnancy and the postpartum period, menopause and aging. They sit, she writes, precisely where biology, lived experience, and structural inequities intersect—and that intersection is where the greatest untapped gains in prevention lie.
The editorial’s central claim is provocative in its simplicity: for women’s cancers, the most powerful tool available to medicine may not be a new drug, a novel biomarker, or a next-generation sequencing platform, but the knowledge that already exists and has not been fully acted upon. Oncology, De Vivo observes, is drawn toward what is mysterious or technologically complex. Yet the four major women’s cancers repeatedly demonstrate that the limiting factor is rarely the science itself. More often, it is political will, health infrastructure, and the distribution of attention and resources that determine whether established interventions actually reach the women who need them.
Cervical cancer is presented as the clearest and most consequential example. Human papillomavirus vaccination combined with modern screening can render this cancer almost entirely preventable. Where these tools are implemented equitably, incidence and mortality plummet; where they are not, women—especially those who are poor, rural, or otherwise marginalized—continue to die of a disease for which effective prevention has existed for years. The editorial is blunt about what this means: the science is not the bottleneck. The failure is one of delivery, and it is measured in lives that could have been saved with vaccines and screening programs that already work.
Breast cancer tells a more complicated story, one of genuine progress shadowed by persistent gaps. Survival has improved substantially, and the understanding of tumor biology has become more nuanced, enabling increasingly targeted therapies. But the editorial highlights a set of unresolved problems that precision medicine has not solved: public confusion about screening remains widespread, investment in primary prevention is limited, and racial and socioeconomic disparities in stage at diagnosis and outcomes persist. De Vivo draws a pointed contrast—clinicians and researchers speak about precision treatment with ease, yet remain far less precise about prevention and about who actually has access to the best care. The implication is that the same rigor applied to molecular subtyping needs to be applied to the social and structural determinants that shape who is diagnosed late and who dies early.
Ovarian cancer represents a different kind of missed opportunity, one that occurs earlier in the disease pathway. Unlike cervical cancer, it lacks an effective population-level strategy for early detection, and primary prevention options beyond women with known high-risk mutations or surgical indications remain elusive. Symptoms are typically vague and easily dismissed, care is frequently delayed, and the epidemiological lens on modifiable risk factors is comparatively underused. The editorial suggests that this underuse is itself a choice—one that reflects where research funding and clinical attention have historically flowed rather than any inherent limit on what epidemiology can contribute. For a cancer so often detected at advanced stages, the potential value of better understanding modifiable risk is difficult to overstate.
Endometrial cancer, the most common gynecologic malignancy in many high-income countries, is the fourth pillar of the argument—and perhaps the most alarming. Its incidence is rising, particularly among younger and minoritized women, and the drivers are well characterized: obesity, metabolic health, hormonal exposures, and body weight across the life course all play central roles. In principle, this should make endometrial cancer a model disease for prevention, a cancer whose trajectory could be bent downward through interventions on known risk factors. Instead, the editorial notes, it remains under-recognized, and stark racial inequities in mortality reveal that access to care, clinician bias, and delayed diagnosis are literally life-and-death issues. A preventable cancer is becoming more common, and the burden is falling disproportionately on the women least equipped to bear it.
Across all four cancers, the editorial identifies a consistent set of themes. Risk factors are, to a meaningful degree, modifiable. Tools that demonstrably work are not equitably delivered. And women’s voices remain underrepresented when research priorities are set and health policy decisions are made. These are not independent problems; they reinforce one another. When the populations most affected by a disease have the least influence over how resources are allocated, the interventions that exist tend to be deployed where they are easiest to deliver rather than where they are most needed. The result is a persistent gap between what medicine knows and what patients experience.
The editorial also serves as a progress report on a concrete effort to change that dynamic. In 2025, Cancer Causes & Control launched a dedicated collection on women’s cancers, aiming to bring these issues into sharper focus. Now in its second year, the collection has drawn strong engagement from researchers, clinicians, and advocates—evidence, De Vivo writes, that there is both energy and appetite for this work. But she is careful to distinguish engagement from impact. The challenge ahead, as she frames it, is to convert that energy into action: to move from describing disparities to dismantling them, and from documenting risk factors to actually preventing disease. Description, in other words, is a necessary but insufficient stage; the standard the journal must now hold itself to is measurable change.
That framing carries implications well beyond a single journal or collection. For researchers, it suggests that studies quantifying yet another disparity or confirming yet another risk association should be designed with an explicit pathway toward intervention. For clinicians, it underscores that prevention counseling, equitable screening outreach, and attention to the social circumstances of patients are not peripheral to oncology but central to it. For policymakers, the message is starker still: the tools to prevent cervical cancer outright, to reduce breast cancer disparities, and to slow the rise of endometrial cancer already exist, and the cost of inaction is counted in preventable deaths. What remains is the harder work of building the infrastructure, funding the programs, and sustaining the political commitment to deliver them.
De Vivo closes with a standard that is both an aspiration and an accountability measure: women deserve nothing less than the full application of what is already known. The editorial does not call for a scientific breakthrough. It calls for something arguably more difficult—the alignment of existing knowledge, existing tools, and existing evidence with the populations that need them most. In an era when cancer research is often celebrated for its technological sophistication, the argument lands with unusual force. The power to prevent many women’s cancers is not waiting to be discovered. It is waiting to be used.
Subject of Research: Prevention and health equity in women’s cancers, including cervical, breast, ovarian, and endometrial cancer
Article Title: Letter from the Editor-in-Chief: Women’s cancers and the power we are not yet using
Article References: De Vivo, I. (2026). Letter from the Editor-in-Chief: Women’s cancers and the power we are not yet using. Cancer Causes & Control, 37(9), Article 154. https://doi.org/10.1007/s10552-026-02233-1
Image Credits: AI Generated
DOI: 10.1007/s10552-026-02233-1
Keywords: women’s cancers, cervical cancer, breast cancer, ovarian cancer, endometrial cancer, HPV vaccination, cancer prevention, health disparities, cancer screening, health equity, obesity and cancer, Cancer Causes & Control
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 22, 2026). Women’s Cancers: The Prevention Power We Already Have but Rarely Use. Scienmag. https://scienmag.com/womens-cancers-the-prevention-power-we-already-have-but-rarely-use/
Nathaniel Bowman. “Women’s Cancers: The Prevention Power We Already Have but Rarely Use.” Scienmag, 22 September 2026, https://scienmag.com/womens-cancers-the-prevention-power-we-already-have-but-rarely-use/. Accessed 22 September 2026.
Nathaniel Bowman. “Women’s Cancers: The Prevention Power We Already Have but Rarely Use.” Scienmag. September 22, 2026. https://scienmag.com/womens-cancers-the-prevention-power-we-already-have-but-rarely-use/
Copy citation Download RIS
Tags: advocacy for increasedand endometrial cancersbarriers to implementing existing women’s cancer knowledgebreast cancerCancer Causes & Controlcancer preventioncancer screeningcervicalcervical cancercomprehensive women’s health and cancer preventionendometrial cancerHealth disparitieshealth equityhealth policy and resource allocation for women’s cancersHPV vaccinationimpact of social determinants on women’s cancer outcomesimportance of screening and early detection in women’s cancersintegrated approach to women’s cancersinterconnectedness of breastObesity and CancerovarianOvarian cancerreproductive life stage and cancer riskrole of biology and lived experience in women’s cancer riskstructural health inequities in women’s cancer preventionwomen’s cancerswomen’s cancers prevention strategies
